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SCIENTIFIC OPINION 
Scientific Opinion on the safety and efficacy of inositol as a feed additive for 
fish, dogs and cats
1 
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
This scientific output, published on 12 December 2014, replaces the earlier version published on 6 May 2014.
4 
ABSTRACT 
Inositol is an essential micronutrient for salmon, carp, tilapia and shrimps, particularly juveniles. This conclusion 
is extended to all fish and crustaceans. The requirements differ among species and may be in the range of 250–
500 mg/kg complete feed for fish. The use of inositol in feed for fish and crustaceans is considered safe at the 
recommended levels; setting a maximum content is not considered necessary. Based on the study provided in 
dogs, it was not possible to (i) demonstrate the essentiality of dietary inositol for dogs and (ii) conclude on the 
safety of dietary inositol at the recommended use levels of between 500 and 3 000 mg/kg. The FEEDAP Panel is 
not in the position to conclude on the efficacy and safety of inositol for cats. Supplementing feed for fish and 
crustaceans will not substantially increase the exposure of the consumer to inositol. Considering dietary exposure 
and endogenous synthesis of inositol, the additional exposure from fish fed an inositol-supplemented diet is of 
no concern for consumer safety. Considering the potential inhalation exposure upon handling the additive and 
the absence of data on inhalation toxicity, the FEEDAP Panel concludes that inhalation exposure from handling 
inositol could be hazardous. In the absence of data, inositol should be considered as irritant to skin and eyes and 
as a skin sensitiser. Inositol occurs naturally in the environment, particularly in plants. The use of inositol in fish 
nutrition  is  not  expected  to  substantially  increase  the  concentration  in  the  environment.  Consequently,  the 
supplementation of fish feed with inositol does not pose a risk to the environment. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Additives  and  Products  or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and 
efficacy of inositol as a nutritional additive to feed and water for drinking for all animal species. 
Inositol, a carbocyclic polyol, is a sugar-like carbohydrate synthesised by most plants and animals. 
Inositol  contributes  to  biological  processes  in  almost  all  tissues,  and  is  a  precursor  of 
phosphatidylinositol, an important component of biological membranes and lung surfactant. Inositol 
plays an important role as the structural basis for a number of secondary messengers in eukaryotic 
cells (e.g. inositol 1,4,5,-triphosphate). 
Inositol is an essential micronutrient for salmon, carp, tilapia and shrimps, particularly juveniles. This 
conclusion is extended to all fish and crustaceans. The requirements differ among species and may be 
in  the  range  of  250–500 mg/kg  complete  feed  for  fish.  The  use  of  inositol  in  feed  for  fish  and 
crustaceans  is  considered  safe  at  the  recommended  levels;  setting  a  maximum  content  is  not 
considered necessary. 
Based on the study provided in dogs, it was not possible to (i) demonstrate the essentiality of dietary 
inositol for dogs and (ii) conclude on the safety of dietary inositol at the recommended use levels of 
between 500 and 3 000 mg/kg. The FEEDAP Panel is not in the position to conclude on the efficacy 
and safety of inositol for cats. 
Supplementing  feed  for  fish  and  crustaceans  will  not  substantially  increase  the  exposure  of  the 
consumer  to  inositol.  Considering  dietary  exposure  and  endogenous  synthesis  of  inositol,  the 
additional exposure from fish fed an inositol-supplemented diet is of no concern for consumer safety. 
Considering the potential inhalation exposure upon handling the additive and the absence of data on 
inhalation  toxicity,  the  FEEDAP  Panel  concludes  that  inhalation  exposure  from  handling  inositol 
could be hazardous. In the absence of data, inositol should be considered as irritant to skin and eyes 
and as a skin sensitiser. 
Inositol occurs naturally in the environment, particularly in plants. The use of inositol in fish nutrition 
is  not  expected  to  substantially  increase  the  concentration  in  the  environment.  Consequently,  the 
supplementation of feed with inositol does not pose a risk to the environment. Inositol for fish, dogs and cats 
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BACKGROUND 
Regulation  (EC)  No  1831/2003
5  establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7; in addition Article 10(2) of that Regulation also specifies that 
for existing products within the meaning of Article 10( 1), an application shall be submitted in 
accordance with Article 7, at the latest one year before the expiry date of the authorisation given 
pursuant to Directive 70/524/EEC for additives with a limited authorisation period, and within a 
maximum of seven years after the entry into force of this Regulation for additives authorised without 
time limit or pursuant to Directive 82/471/EEC. 
The  European  Commission  received  a  request  from  the  VITAC  EEIG  Vitamins  Authorisation 
Consortium
6for
  authorisation  of  a  new  use  (i.e.  use  in  water  for  drinking)  and  re-evaluation  of 
authorisation of inositol, when used as a feed additive for all animal species (category: nutritional 
additive;  functional  group:  vitamins,  provitamins  and  chemically  well-defined  substances  having 
similar effect) under the conditions mentioned in Table 1.
7 
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application to the European Food Safety Authority (EFSA) as an application under Article 4(1) 
(authorisation of a feed additive or new use of a feed additive) and under Article 10(2) (re -evaluation 
of an authorised feed additive).  EFSA received directly from the applicant the technical dossier in 
support of this application.
8 According to Article 8 of that Regul ation, EFSA, after verifying the 
particulars and documents submitted by the applicant, shall undertake an assessment in order to 
determine whether the feed additive complies with the conditions laid down in Article 5. The 
particulars and documents in suppo rt of the application were considered valid by EFSA as of  18 
November 2011. 
Inositol has been authorised without time limit under Council Directive 70/524/EEC
9 for its use for all 
animal species as a nutritional additive. 
The Panel on Food Additives and Nutrient Sources added to food (ANS) issued an opinion on the use 
of  Inositol hexanicotinate (inositol hexaniacinate) as a source of niacin (vitamin B 3)  added  for 
nutritional purposes in food supplements (EFSA, 2009). The NDA Panel expressed an opinion on the 
substantiation of health claims related to inositol and cognitive function (ID 1588) pursuant to Article 
13(1) of Regulation (EC) No 1924/2006 (EFSA NDA Panel, 2009). 
TERMS OF REFERENCE 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety for the target animals, consumer, user and the environment and the efficacy of inositol, when 
used under the conditions described in Table 1. 
                                                       
5  Regulation (EC) 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in 
animal nutrition. OJ L 268, 18.10.2003, p. 29. 
6  On 13 March 2013, EFSA was informed by the applicant that VITAC EEIG was liquidated on 19 December 2012 and their 
rights as applicant were transferred to FEFANA asbl (EU Association of Specialty Feed Ingredients and their Mixtures), 
representing notably the following company: Trouw Nutritional International B.V. Avenue Louise, 130A, Box 1, 1050 
Brussels, Belgium.  
7  On 31 July 2013, EFSA was informed by the applicant of the following: target species changed from ‘all animal species’ to 
‘fish, cats and dogs’. 
8  EFSA Dossier reference: FAD-2010-0196. 
9  Commission list of the authorised additives in feedingstuffs published in application of Article 9t (b) of Council Directive 
70/524/EEC concerning additives in feedingstuffs (2004/C 50/01). OJ C 50, 25.2.2004, p. 1. Inositol for fish, dogs and cats 
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Table 1:  Description and conditions of use of the additive as proposed by the applicant  
Additive   Inositol      
Registration number/EC No/No 
(if appropriate)  Not appropriate 
Category(ies)  of additive  3. Nutritional additives 
Functional group(s) of additive  (a)  Vitamins,  pro-vitamins  and  chemically  well  defined  substances 
having a similar effect 
 
Description 
Composition, description  Chemical formula  Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Inositol 
IUPAC name:  
cis-1,2,3,5-trans-
4,6-
Cyclohexanehexol 
Chemical formula: 
C6H12O6 
CAS number: 
87-89-8 
Minimum 97 % of 
inositol 
Microbiological 
activity analysis 
 
Trade name   Not appropriate 
Name  of  the  holder  of 
authorisation 
Not appropriate 
 
Conditions of use 
Species  or 
category  of 
animal 
Maximum Age 
Minimum content  Maximum content  Withdrawal 
period  mg /kg of complete feedingstuffs   
Fish 
 
Cats 
 
Dogs 
No restrictions - 
during all life 
cycle  
Not applicable  Not applicable  Not appropriate 
 
Other provisions and additional requirements for the labelling 
Specific  conditions  or  restrictions 
for use  Not appropriate  
Specific  conditions  or  restrictions 
for handling   Handle in accordance with good industrial hygiene and safety practices. 
Post-market monitoring   Not appropriate 
Specific  conditions  for  use  in 
complementary feedingstuffs  Not appropriate 
 
Maximum Residue Limit (MRL)  
Marker residue  Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content 
in tissues 
Not appropriate  Not appropriate  Not appropriate  Not appropriate 
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ASSESSMENT 
This opinion is based in part on data provided by a consortium representing a single company involved 
in the production and distribution of inositol. It should be recognised that these data cover only a 
fraction of existing additives containing inositol. The application is for the active substance and the 
composition of the additive formulations is not the subject of the application. The Panel has sought to 
use the data provided, together with data from other sources, to deliver an opinion. 
1.  Introduction 
Inositol, a carbocyclic polyol, is a sugar-like carbohydrate synthesised by most plants and animals. It 
exists in nine possible stereoisomers, four of which are physiologically active. The predominant form 
in plants and animals is myo-inositol. Other naturally occurring isomers (though in minimal quantities) 
are scyllo-, muco-, D-chiro- and neo-inositol, and possible isomers are L-chiro-, allo-, epi- and cis-
inositol. In plants, phosphorus is stored mainly as hexa- and penta-inositol phosphate (phytate). 
Inositol contributes to biological processes in almost all tissues, as a precursor of phosphatidylinositol, 
an important component of biological membranes and lung surfactant. Inositol plays an important role 
as the structural basis for a number of secondary messengers in eukaryotic cells (e.g. inositol 1,4,5-
triphosphate). 
Inositol is included in the European Union Register of Feed Additives pursuant to Regulation (EC) 
No 1831/2003 and is foreseen for re-evaluation. Inositol is applied for re-evaluation as a nutritional 
additive,  functional  group  vitamins,  pro-vitamins  and  chemically  well-defined  substances  having 
similar effects. It is intended to be added to feed for fish, cats and dogs. 
myo-Inositol is described in the European Pharmacopoeia (PhEur), monograph (MG) 1805. 
Inositol is listed as a pharmacologically active substance in veterinary medicinal products
10 and is not 
subject to maximum residue levels when used in food -producing animals. Inositol  is listed as an 
ingredient in cosmetic products as an antistatic, humectant and hair-conditioning agent.
11 
Inositol  hexanicotinate  is authorised for addition for  specific nutritional purposes in  to  foods for 
particular nutritional uses  as a source of niacin .
12 Inositol can be added  to processed cereal-based 
foods and baby foods for infants and young children
13 and to infant formulae and follow-on formulae 
when reconstituted as instructed by the manufacturer.
14 
2.  Characterisation 
2.1.  Characterisation of the active substance 
The active substance is identical to the additive. 
myo-Inositol,  with  the  generic  name  inositol,  is  defined  by  the  International  Union  of  Pure  and 
Applied  Chemistry  (IUPAC)  as  cis-1,2,3,5-trans-4,6-cyclohexanehexol  (synonyms: 
(1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol, cyclohexanehexol)  with the Chemical  Abstracts 
                                                       
10 Commission  Regulation  (EU)  37/2010  of  22  December  2009  on  pharmacologically  active  substances  and  their 
classification regarding maximum residue limits in foodstuffs of animal origin. OJ L 15, 20.1.2010, p. 1. 
11 Commission Decision 2006/257/EC of 9 February 2009 amending  Decision 96/335/EC establishing an inventory and a 
common nomenclature of ingredients employed in cosmetic products. OJ L 97, 5.4.2006, p. 1. 
12 Commission Regulation (EC) No 953/2009 of 13 October 2009 on substances that may be added for specific nutritional 
purposes in foods for particular nutritional uses. OJ L 269, 14.10.2009, p. 9. 
13 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children. OJ L 339, 6.12.2006, p. 16. 
14 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and  follow-on formulae and amending 
Directive 1999/21/EC. OJ L 401, 30.12.2006, p. 1. Inositol for fish, dogs and cats 
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Service  (CAS)  number  87-89-8  and  the  European  Inventory  of  Existing  Chemical  Substances 
(EINECS) number 201-781-2. The structural formula of myo-inositol is shown in Figure 1. 
           
Figure 1:   Structural formula of myo-inositol 
The molecular formula of inositol is C6H12O6 and its molecular weight is 180.16. It has a melting point 
of 225–227 °C, a bulk density of 0.45 g/cm
3 and a density of 1.752 g/cm
3. It is very soluble in water 
(14 g dissolves in 100 mL). The pH of an aqueous solution is approximately neutral. 
Inositol is a white or almost white crystalline odourless powder with a very slight sweet taste. 
By specification, the additive contains ≥ 97.0 % myo-inositol (anhydrous substance) in compliance 
with  PhEur  (97.0–102.0 %,  anhydrous  substance).  Analysis  of  five  batches  of  inositol  under 
application, each by a separate laboratory (method not given and producer(s) unknown) showed an 
average  of  99.5 %  anhydrous  inositol  (range  99.3–99.9 %).
15  The  product  (three  batches)  also 
complied with the thresholds of PhEur for substance-related impurities (impurity A (D-mannitol) and 
impurity  B  (propane-1,2,3-triol  or  glycerol),  < 0.3 %  each;  total  impurities  including  unspecified 
related substances, < 1.0 %) and for lead (< 0.5 mg/kg).
16 In three batches of the product, the arsenic 
content was < 0.1 mg/kg, the lead content was < 0.05 mg/kg, the cadmium and mercury contents were 
< 0.01 mg/kg and the sum of dioxins and dioxin-like polychlorinated biphenyls (PCBs) was < 0.128ng 
WHO-PCCD/F-PCB-TEQ  (World  Health  Organization  PCDD,  PCDF  and  PCB  toxic 
equivalents)/kg.
17 
In total, four batches of inositol were analysed for particle size distribution by laser diffractio n. The 
amount (v/v) of the particle fractions < 50 µm and < 10 µm diameter in three batches was 69 to 72 % 
and 22 to 29 %, respectively, and in the fourth batch was 16 % and 1.5 %, respectively.
18 The dusting 
potential measured according to  the Stauber–Heubach method in three batches ranged between 0.28 
and 1.14 g/m
3.
19 
2.2.  Manufacturing process 
Hydrolysis of natural phytic acid (phytate) at  8 Pa and 150 C leads to crude inositol in a water 
solution.  Phosphorous  (P)  is  then  precipitated  as  calcium  phosphate  by  the  addition  of  calcium 
hydroxide.  Calcium  phosphate  is  removed  by  filtration  and  water  is  evaporated  under  vacuum. 
Cooling down to room temperature makes the inositol crystallise. Crystallisation is repeated and the 
product discolours with active carbon. The moist finished product is dried in a hot air oven at 120 C. 
The applicant provided a flow chart and detailed description of the manufacturing process, and critical 
control points are identified and monitored. 
                                                       
15 Technical dossier/Section II/Annex_II_1. 
16 Technical dossier/Supplementary information/February 2013/Annex A. 
17 Technical dossier/Section II/Annex_II_2. 
18 Technical dossier/Section II/Annex_II_3. 
19 Technical dossier/Supplementary information February 2013/Annexes B and C. Inositol for fish, dogs and cats 
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2.3.  Stability and homogeneity 
2.3.1.  Shelf life 
Inositol (three batches of one producer, stored in double polyethylene bags in  a fibre drum) was 
demonstrated to have a shelf life of 48 months at 25 °C.
20 The additive (four batches) was shown to be 
stable at 40 °C for three months.
21 
2.3.2.  Stability in premixtures and feed 
Inositol (three batches) was added to a vitamin–mineral premixture (without choline chloride) for pigs 
at a concentration of 15 g/kg. Samples were stored in polyethylene bottles at 25 °C and 40 °C for up to 
six months. Results showed a 4 % and 8.5 % reduction in the content of inositol after six months at 
25 C and 40 C, respectively.
22 
The stability of inositol (one batch) was  further investigated when added to a premixture cont aining 
trace elements and choline chloride (20 g/kg) at the inclusion level of 15 g/kg. The measured initial 
value was lower than intended (13 g/kg). Final recovery after six months was 11 g/kg.
23 
Inositol (three batches) was incorporated in a complete feed for pigs at a level of 150 mg/kg. Samples 
were stored for three months at 25 °C. The inositol was analysed after hydrolysis of the samples. The 
initial analytical values were  10 times higher than the supplemental level, indicating high levels of 
background inositol. During storage, variable results (decrease as well as increase of the total inositol 
content) were observed.
18 
The effect of feed processing (extrusion) and storage was studied in fish feed. The basal feed for 
salmon  contained  high  levels  of  fish  meal  and  fish  oil  but  also  considerable  amounts  of  wheat, 
soybean  and  rapeseed  meal.  The  basal  diet  (background  about  1 200 mg  inositol/kg)  was 
supplemented with 0, 250 and 500 mg inositol/kg. The supplemented inositol was not fully recovered 
(about 70–80 %). Total inositol was reduced by extrusion by about 200 mg/kg in all feeds. It remained 
essentially unchanged during a six-month storage period.
24 
2.3.3.  Homogeneity 
The capacity of inositol to homogeneously distribute in fish feed was calculated on the basis of 10 
sub-samples,  each  from  both  meal  and  extruded  feed,  each  unsupplemented  and  supplemented 
(250 mg/kg).  In  all  cases,  the  coefficient  of  variation  was  < 9 %.
23  The  experimental  set-up  is 
unsuitable to measure the homogeneous distribution, since the added quantity was only 20–30 % of 
the background concentration. 
2.4.  Physico-chemical incompatibilities in feed 
No physico-chemical incompatibilities or interactions have been reported between inositol and feed 
materials or carriers when the additive was added to premixtures and feed. No such incompatibilities 
or interactions are expected. 
2.5.  Conditions of use 
Inositol is intended for use in feed for fish, cats and dogs without a maximum limit and withdrawal 
period.  The  recommended  use  level  for  salmonids  is  350–500 mg  inositol/kg  feed,  the  typical 
supplementation  level  in  pet  food  ranges  from  500 mg/kg  to  3 000 mg/kg.  The  additive  can  be 
administered to feed via premixtures or directly to complete or complementary feed. 
                                                       
20 Technical dossier/Section II/Annex_II_7. 
21 Technical dossier/Section II/ Annex_II_8. 
22 Technical dossier/Section II/Annex_II_9. 
23 Technical dossier/Supplementary information/February 2013/Annex E. 
24 Technical dossier/Supplementary information/February 2013/Annex F. Inositol for fish, dogs and cats 
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2.6.  Evaluation of the analytical methods by the European Union Reference Laboratory 
(EURL) 
EFSA has verified the EURL report as it relates to the methods used for the control of inositol in 
animal feed. The Executive Summary of the EURL report can be found in the Appendix. 
3.  Absorption, distribution, metabolism and excretion (ADME) 
Inositol occurs in nature in both free and bound (inositol phosphates and phosphatidylinositol) forms. 
Free inositol is extensively absorbed (> 90 %, according to Nahapetian and Young, 1980) by active 
transport in the small intestine (Caspary and Crane, 1970). Inositol from dietary phosphoinositol, a 
minor component of phospholipids, is similarly absorbed extensively as lysophosphatidylinositol after 
removal of the fatty acid at the syn-2 position of glycerol by pancreatic phospholipases (Cohn et al., 
2010). The bioavailability of myo-inositol from inositol hexaphosphate (phytic acid) is very limited 
and depends on a variety of factors, for example phytate solubility, minerals, plant phytases, intestinal 
microbial phytases, supplemented phytases, and food processing (Nolan et al., 1987; Sandberg et al., 
1989; Sakamoto et al., 1993; Sandberg, 2002; Sandberg and Andlid, 2002; Abebe et al., 2007; Kumar 
et al., 2012). 
Inositol is widely distributed in the organism. Inositol is incorporated in the phospholipid pool, in 
particular  as  phosphatidylinositol,  a  component  of  cell  membranes  (Holub,  1986).  In  male  rats, 
injected  radiolabelled  inositol  is  concentrated  mainly  in  the  liver,  whereas  small  amounts  of 
accumulation do occur in muscle tissue and not at all in adipose tissue (Lewin et al., 1976). In young 
rats, dietary concentrations of 1 500 mg/kg had no significant influence on liver deposition compared 
with counterparts fed a purified myo-inositol-free diet (Burton et al., 1976), whereas 5 000 mg myo-
inositol/kg diet increased the levels of myo-inositol in the liver and kidney (Burton and Wells, 1976). 
Endogenous inositol is synthesised mainly in the kidney, and concentrations of free inositol in the 
renal medullary cells are 1 000-fold higher than in blood (García-Pérez and Burg, 1991); in humans, 
about  4 g/day  are  estimated  to  be  produced  (Clements  and  Diethelm,  1979).  Plasma  levels  are 
regulated  by  the  kidneys  through  glomerular  filtration,  reabsorption  in  the  renal  medulla  and 
catabolism  or  excretion  (Holub,  1986;  García-Pérez  and  Burg,  1991).  Studies  with  radiolabelled 
inositol indicate that the capacity of the kidneys to catabolise inositol is much higher than the capacity 
to  excrete  unchanged  inositol  (García-Pérez  and  Burg,  1991).  In  tissues  of  mammals,  including 
humans, myo-inositol can be converted to either L- or D-chiro-inositol by epimerases (see Carlomagno 
and Unfer, 2011). Inositol is catabolised to D-glucuronic acid; through subsequent metabolic steps, O-
xylulose 5-phosphate is produced and enters the pentose phosphate cycle. 
4.  Efficacy and safety of inositol in fish, dogs and cats 
Efficacy and safety are based on the same datasets; therefore, they are assessed in the same section. 
4.1.  Fish 
In  fish,  deficiency  of  myo-inositol results  in  anorexia,  lethargy,  dark  skin  coloration, erosion, fin 
degeneration, loss of skin mucosa, oedema, anaemia, reduced growth and inefficient feed conversion, 
as well as a decreased activity of cholinesterase and certain aminotransferases, increased neutral lipids 
and reduced phospholipids in liver (Halver, 1982; Holub et al., 1982; NRC, 2011). Requirements are 
not well established and may vary among species. According to NRC (2011), the general requirements 
of inositol for fish seem to be in the range of 250–500 mg/kg diet based on studies with purified diets. 
Recommendations  for  salmonids  are  350–500 mg  supplemental  inositol/kg  complete  feed  (AWT, 
2002),  considering  the  variability  in  the  background  inositol  content  and  its  availability  in  feed 
materials. 
Shiau and Su (2005) studied the effect of increased supplementation of inositol up to two-fold the 
recommended dose (0, 150, 250, 350, 450, 600 and 1 200 mg/kg semi-purified diet without inositol) in 
juvenile hybrid tilapia (Oreochromis niloticus × Oreochromis aureus, 0.51 g initial body weight (bw)) Inositol for fish, dogs and cats 
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for eight weeks. The inositol content was confirmed by analysis. Three aquaria with 15 fish each were 
used  per treatment.  Feed was  offered  at  a rate  5 %  bw/day  divided in two meals.  There  was  no 
significant effect on mortality. Broken-line analysis of body weight gain suggested a requirement of 
about  400 mg  inositol/kg.  Liver  lipids  decreased  from  6.0 g/100g  wet  tissue  without  inositol 
supplementation  to  4.4 g  at  350 mg  supplemental  inositol/kg  without  further  reduction  at  higher 
inositol concentrations. 
Jiang et al. (2009a) studied the effect of supplemental myo-inositol in diets for juvenile Jian carp 
(Cyprinus carpio var. Jian) on growth, digestion and antioxidant potential in a 60-day trial. The diets 
were calculated to contain a total inositol background level of 171 mg/kg, increasing to 250, 400, 550, 
700, 850 and 1 000 mg/kg by addition of inositol. The content of inositol in experimental diets was 
analytically confirmed. Group size was 150 carps (22 g initial bw) in three glass aquaria with 50 carps 
in each. Feed was given  eight times per day to apparent satiation for 60 days. Survival was not 
reported. There was a linear increase of growth and feed intake up to 550 mg inositol/kg. The final 
body weight of this group (92 g) was not different from that of the highest total inositol content in the 
diet. Another study by the same authors (Jiang et al., 2009b) did not contribute to identifying different 
requirements or safety levels. 
Shiau and Su (2004) studied the effect of increasing supplemental inositol (up to 8 000 mg/kg semi-
purified diet, background 8 mg inositol/kg) on grass shrimps (Penaeus monodon, giant tiger prawn) 
for eight weeks. The group size was 45 individuals (3 replicates with 15 shrimps in each, initial bw 
0.44 g).  Feeding  rate  was  8 %  of  body  weight.  Weight  gain  analysis  (broken-line  model)  would 
indicate that the requirement for dietary myo-inositol might be about 3 400 mg/kg. Survival was low 
and  was  related  to  dose  (41,  44,  52  and  57 %  at  250,  500,  1 000  and  2 000 mg  supplemented 
inositol/kg,  respectively)  and  reached  the  highest  level  (70 %)  at  4 000 mg  supplemental  inositol. 
However, considerable leaching of inositol was observed (43, 62 and 79 % after 30, 60 and 120 
minutes, respectively) and feed consumption data were not provided. It can be concluded that inositol 
is required for survival and optimal growth of prawns. However, owing to leaching, any conclusion on 
the quantities required or considered safe is not possible. 
Atlantic salmon (Salmo salar L.) fry (0.19 g bw) were fed diets consisting mainly of fish meal, soy 
concentrate and fish oil and containing 296 mg inositol/kg, supplemented with 0, 100, 200, 400, 800 
or  1 600 mg  inositol/kg  for  28  weeks  (Waagbø  et  al.,  1998).  Intended  values  were  analytically 
confirmed. Initially, there were two tanks with 1 000 fry in each, but this reduced to 600 after 16 
weeks. At the end of the study, supplemental inositol did not affect body weight (about 24 g final bw), 
mortality (2.7–5.4 %) or body composition. No data, including liver lipids after eight-week feeding, 
demonstrated an inositol requirement of salmon above 300 mg/kg feed. At the end of the experiment, 
haemoglobin concentration increased with dietary levels of inositol, but there were no significant 
differences  between  the  supplemented  and  the  control  groups.  At  the  same  time,  triacylglycerol 
plasma  levels  were  negatively  correlated  with  dietary  inositol  supplementation  (P < 0.01).  On  the 
other  hand,  the  data  show  that  levels  up  to  2 200 mg  analytically  determined  inositol/kg 
(corresponding  to  1 600 mg  supplemented  inositol/kg)  did  not  result  in  adverse  effects.  This 
corresponds to four times the highest recommended supplementation level. 
4.2.  Dogs and cats
25 
No deficiencies of inositol have been documented in either dogs or cats (NRC, 2006). Consequently, 
no requirement has been established by the National Research Council (NRC). 
Watson et al. (2006) studied the influence of inositol on canine epidermal barrier function in vivo as 
measured by transepidermal water loss (TEWL). Thirty-two Labrador retrievers (3–12 years old) were 
divided into two sex- and age-matched groups and fed a basal diet containing 80 mg inositol/400 kcal 
and an experimental diet containing 230 mg inositol/400 kcal for 12 weeks. These values correspond 
to  720  and  2 070 mg/kg  assuming  that  a  typical  dry  dog  food  contains  3 600 kcal/kg.  However, 
                                                       
25   This section has been amended following the provisions of Article 8(6) and Article 18 of Regulation (EC) No 1831/2003. Inositol for fish, dogs and cats 
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inositol  was  not  the  only  variable  in  the  study  design;  inositol  was  added together  with  choline, 
pantothenate, nicotinamide and histidine. The composition of the basal diet was not reported. Barrier 
function  was  measured  using  TEWL.  It  was  found  that  a  combination  of  pantothenate,  choline, 
nicotinamide,  histidine  and  inositol,  when  fed  at  supplemented  concentrations,  was  able  to 
significantly reduce TEWL in dogs at the earliest after nine weeks. However, in vitro data on ceramide 
and total lipid synthesis and transepidermal diffusion rate did not indicate any effect of inositol alone 
but in combination with choline. In the view of the FEEDAP Panel, these data are not sufficient to 
support that inositol has a role in the epidermal barrier function in dogs and can, therefore, not be 
taken as a demonstration of essentiality of inositol. 
The applicant provided additional studies on Labrador retrievers
26 and on cats
27. However, the data 
were not considered by the FEEDAP Panel because of the inherent weakness of the study design and 
reporting. 
4.3.  Conclusions on efficacy and safety of inositol in target animals 
Inositol  is  an  essential  micronutrient  (a  chemically  defined  substance  having  similar  effects  as  a 
vitamin) for salmon, carp, tilapia and shrimps, particularly juveniles. This conclusion is extended to all 
fish  and  crustaceans.  The  requirements  differ  among  species  and  may  be  in  the  range  of  250–
500 mg/kg complete feed for fish. The use levels recommended by the applicant are in the same range. 
A level four times the highest recommended supplementation level was found to be safe for salmon. A 
level twice the highest recommended level was shown to be safe for tilapia and carp. No specific 
endpoint  indicating  intolerance  was  identified.  Therefore,  the  use  of  inositol  in  feed  in  fish  and 
crustaceans  is  considered  safe  at  the  recommended  levels;  setting  a  maximum  content  is  not 
considered necessary. 
Based on the study provided in dogs, it was not possible to (i) demonstrate the essentiality of dietary 
inositol for dogs and (ii) conclude on the safety of dietary inositol at the recommended use levels 
between 500 and 3 000 mg/kg, since the highest level tested was 2 070 mg/kg. The FEEDAP Panel is 
not in the position to conclude on the efficacy and safety of inositol for cats. 
5.  Safety for the consumer 
5.1.  Toxicological studies and observations in humans 
No conventional toxicological studies are available, but the results of studies in rodent models of 
chronic diseases (including diabetes and cancer) suggest that the toxicity of inositol is low. The only 
adverse effects observed were thickening of basement membranes of capillaries of the retina and 
glomeruli of non-diabetic rats treated for nine months with 2 % myo-inositol in the diet (equivalent to 
1 800 mg/kg bw per day, using the EFSA default conversion factor of 0.09 for sub-chronic exposure 
of rats) and worsening of the capillary thickening in glomeruli along with an increase in the amount of 
pericyte-containing capillaries in the retina of diabetic and non-diabetic rats treated for five or nine 
months with 2 % myo-inositol in the diet (Tilton et al., 1993). A no observed adverse effect level 
(NOAEL) could not be determined, as only one dose level was used. Other studies comparing effects 
of inositol in diabetic and non-diabetic rats (Pugliese et al., 1990; Coppey et al., 2002) showed that 
dietary levels of 0.5 to 2 % inositol (equivalent to 450 to 1 800 mg/kg bw per day) reduced some of 
the metabolic, neurological and circulatory changes of diabetes, but the treatments either had no effect 
on these parameters in non-diabetic rats (Pugliese et al., 1990) or were not tested in non-diabetic rats 
(Coppey et al., 2002). 
The effect of inositol on cancers induced by other chemicals has been investigated in mice. Liao et al. 
(2007)  used  long-term  exposure  in  drinking  water  to  cyclic  dextran  sulphate  sodium  (DSS)  in 
                                                       
26 Technical dossier/Supplementary information/January 2014/Annex A and Appendix A. 
27 Technical dossier/Supplementary information/January 2014/Annex B, Appendix B1 and Appendix B2. Inositol for fish, dogs and cats 
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combination with an iron-enriched diet to induce ulcerative colitis (which is associated with colon 
cancer) in female C57BL/6 mice. myo-Inositol or hexaphosphate inositol was given at 1 % (equivalent 
to 9 000 mg/kg bw per day) in the drinking water of groups of colitis-induced or non-induced mice for 
255 days. None of the treatments affected mortality, body weight gain or feed consumption. Both 
forms of inositol decreased the number and size of colo-rectal tumours in the colitis-induced groups. 
No colorectal tumours were found in untreated controls or non-induced groups given myo-inositol or 
hexaphosphate inositol. 
Another group of studies (Kassie et al., 2008, 2010a, b) was designed to investigate the effect of 1 % 
dietary myo-inositol (equivalent to 2 000 mg/kg bw per day) in combination with various doses of 
dietary N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine (APTCC) on the production of cancer by 
tobacco smoke carcinogens given by gavage to female A/J mice. Animals were killed after 27 or 44 
weeks of treatment. Body weights and weights of liver and kidneys were not affected by the myo-
inositol/APTCC treatment in either carcinogen-exposed or unexposed groups. myo-Inositol reduced 
the total number of lung tumours and the number of lung adenocarcinomas produced by the treatment 
with tobacco carcinogens, inhibiting cancer cell proliferation and Akt phosphorylation (part of the 
insulin signalling pathway) and inducing apoptosis. Histopathology of the major organs showed no 
further changes in any groups other than an increase in the frequency of eosinophilic bodies in the 
cytoplasm of urinary bladder epithelial cells that was proportional to the dose of APTCC and thus 
unlikely to be a result of the inositol. 
A  review  of  12  controlled  clinical  trials  in  a  total  of  250  adults  given  oral  doses  of  4  to  30 g 
inositol/person per day (equal to 67 and 500 mg/kg bw per day for a 60 kg person) over 1 to 12 
months, found that the most frequently reported and dose-related adverse effects were flatulence, loose 
stools and diarrhoea (Carlomagno and Unfer, 2011). 
Hallman et al. (1986) compared a test group of 37 pre-term infants given an intragastric dosage of 
160 mg inositol/kg bw per day for 10 days (or 75 % of this dose intravenously on occasions when 
enteral dosing was not possible) with a placebo control given glucose in place of inositol. Compared 
with  the  placebo  control  group,  the  test  group  had  lower  mortality,  required  less  mechanical 
ventilation (for their respiratory distress syndrome), had fewer cases of bronchopulmonary dysplasia 
and had less failures of indomethacin-induced closure of the ductus arteriosus. Friedman et al. (2000) 
compared groups of 24 pre-term infants given, by full enteral feeding, infant formulae containing 242, 
710 or 2 500 µmol inositol/L at a rate of 150 mL/kg bw per day (i.e. 36, 107 or 375 µmol/infant per 
day; equivalent to 3.3, 9.5 or 34 mg/kg bw per day for a 2 kg bw pre-term infant) for 30 days. Infants 
given the high dose had a lower incidence of severe retinopathy of prematurity than those given the 
low dose. Other parameters, including body weight gain and the need for mechanical ventilation, were 
unaffected by the treatment. Although the studies in pre-term infants were not designed to identify 
adverse effects, the data provide some assurance that inositol is well tolerated in humans. 
5.1.1.  Conclusions on toxicology 
Rodent studies of effects of inositol on a limited range of parameters mostly showed no adverse effects 
over an oral dose range of 450–9 000 mg/kg bw per day. Only one study showed any adverse effects 
(at 1 800 mg/kg bw per day) but a NOAEL could not be identified. Investigations of effects in adult 
humans and premature babies also considered only a limited range of parameters. Only minor adverse 
effects were reported when oral doses of 67–500 mg/kg bw per day were given to adults. Limited data 
on premature babies treated with inositol also suggest that inositol is well tolerated in humans. 
Although the available studies suggest a low toxicity of myo-inositol in both rodents and humans, the 
data are too limited to allow an upper tolerable intake level (UL) to be defined. 
5.2.  Inositol in tissues and carry over to animal products 
The current analytical methods available for myo-inositol analysis in biological materials quantitate 
either  the  ‘free’  (unbound)  amount  or  the  total  amount.  One  of  the  major  drawbacks  with  total Inositol for fish, dogs and cats 
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methods is the uncertainty on the completion of the hydrolysis of the phosphate forms of myo-inositol. 
Acid hydrolysis (6N HCl) at 120 °C (autoclave) has been found to liberate more than 90 % of myo-
inositol from phosphoinositides, including phytates (Ellingson et al., 2012). In a survey performed in 
the  USA  on  487 foods  (Clements  and  Darnell,  1980), total  myo-inositol  was  measured  using  the 
analytical method described above. It was observed that the greatest amounts of myo-inositol were 
present in fruit, beans, grains and nuts (range 0.6–11.5 g/kg), the highest concentrations reflecting the 
high content of phytates. In contrast, lower concentrations of total myo-inositol were found in animal 
products (meat, 0.06–0.40 mg/kg, with the exception of liver, 1.0–1.7 g/kg; fish, 0.02–0.15 g/kg; eggs, 
0.09 g/kg whole, 0.34 g/kg yolk). A summary of the available data in the literature from Europe (Souci 
et al., 2008), without reference to the analytical methods used, are in line with these results. These 
values are consistent with the fact that free inositol is a highly hydrophilic compound with no affinity 
for lipids. Additional dietary exposure (400, 800 and 1 600 mg inositol/kg feed) of fish for 28 weeks 
resulted  in a  mean  inositol  concentration  of  0.163 g  inositol/kg  whole  body  (mean  of  all levels), 
0.125 g being measured in the unsupplemented control group (Waagbø et al., 1998). These data show 
that feed supplementation with inositol does not lead to considerable bioaccumulation. 
Inositol is also normally present in the milk of mammals, including humans; in cows’ milk, levels are 
between 0.027 and 0.049 g/L (Ogasa et al., 1975; Byun and Jenness, 1982; Souci et al., 2008). In 
cows’  milk,  phospholipids  represent  0.25–0.96 %  of  the  fat,  of  which  7.7 %  corresponds  to 
phosphoinositol, representing 0.006–0.026 g/L (Contarini and Povolo, 2013). 
5.3.  Assessment of consumer safety 
myo-Inositol is found in mixed diets (animal and plant food sources) of humans, under its three main 
forms already described. Data from the 1980s estimated the normal dietary intake of total inositol in 
the USA to be in the range 0.235–1.5 g/person per day (Clements and Darnell, 1980; as cited by 
EFSA, 2009). 
The use of inositol in feedingstuffs for food-producing animals is restricted to fish. The contribution of 
fish  to  consumer  exposure,  calculated  from  background  levels  of  total  inositol  measured  in  fish 
samples  (maximum  concentration reported,  0.15 g/kg;  Clements  and  Darnell, 1980) and  based  on 
maximised exposure (300 g fish/person per day), indicate a value of 0.045 g inositol/person per day. 
Based on the EFSA database (EFSA, 2011) (165 g fish and sea food per day) the contribution would 
represent about 0.025 g inositol/person per day. Considering that the supplementation of fish feed with 
1 600 mg inositol/kg feed for 28 days increases inositol deposition in the flesh by 30 % (see section 
4.1.2),  the  consumer  exposure  would  become  0.059 g  inositol/person  per  day.  That  very  limited 
increase of consumer exposure (0.034 g inositol/day) should be put into perspective by comparing it 
with  the  endogenous  inositol  production  in  humans  (about  4 g  inositol/person  per  day)  and  the 
background  contribution  of  the  diet  (0.235–1.5 g/person  per  day).  The  results  of  the  limited 
toxicological studies further support the safety of these levels of consumer exposure to inositol. 
5.4.  Conclusions on the safety for consumers 
Inositol is a natural constituent of the human diet and has low oral toxicity. Supplementing feed for 
fish  and  crustaceans  will  not  substantially  increase  the  exposure  of  the  consumer  to  inositol. 
Considering dietary exposure and endogenous synthesis of inositol, the additional exposure from fish 
fed inositol-supplemented diets does not give rise to concern for consumer safety. 
6.  Safety for the user 
6.1.  Effects on the respiratory system 
The dusting potential of three batches of inositol was determined to be up to 1.14 g/m
3. Therefore, 
handling the additive may lead to inhalation exposure of users. Inositol for fish, dogs and cats 
 
EFSA Journal 2014;12(5):3671  14 
No acute inhalation toxicity study was provided. It would be prudent to assume that inhalation of dust 
from the additives presents a health hazard to workers and measures should be taken to minimise 
inhalation exposure. 
6.2.  Effects on the eyes and skin 
Inositol is used as an ingredient in cosmetic products. Notwithstanding the large number of data on the 
skin and hair care effects of inositol upon topical use, no studies to identify its potential for skin and 
eye  irritation  and  skin  sensitisation  were  provided.  In  the  absence  of  data,  the  FEEDAP  Panel 
considers it prudent to assume that inositol is irritant to skin and eyes and is a skin sensitiser. 
6.3.  Conclusions on user safety 
Considering the potential inhalation exposure upon handling the additive and the absence of data on 
inhalation  toxicity,  the  FEEDAP  Panel  concludes  that  inhalation  exposure  from  handling  inositol 
could be hazardous. 
In  the  absence  of  data,  inositol  should  be  considered  as  irritant  to  skin  and  eyes  and  as  a  skin 
sensitiser. 
7.  Safety for the environment 
Inositol is widely present in plants as a natural component. The use of inositol in fish nutrition is not 
expected  to  substantially  increase  the  concentration  in  the  environment.  Consequently,  the 
supplementation of fish feed with inositol does not pose a risk to the environment. 
8.  Post-market monitoring 
The  FEEDAP  Panel  considers  that  there  is  no  need  for  specific  requirements  for  a  post-market 
monitoring  plan  other  than  those  established  in  the  Feed  Hygiene  Regulation
28  and  Good 
Manufacturing Practice. 
CONCLUSIONS 
Inositol is an essential micronutrient for salmon, carp, tilapia and shrimps, particularly juveniles. This 
conclusion is extended to all fish and crustaceans. The requirements differ among species and may be 
in  the  range  of  250–500 mg/kg  complete  feed  for  fish.  The  use  of  inositol  in  feed  for  fish  and 
crustaceans  is  considered  safe  at  the  recommended  levels;  setting  a  maximum  content  is  not 
considered necessary. 
Based on the study provided in dogs, it was not possible to (i) demonstrate the essentiality of dietary 
inositol for dogs and (ii) conclude on the safety of dietary inositol at the recommended use levels 
between 500 and 3 000 mg/kg. The FEEDAP Panel is not in the position to conclude on the efficacy 
and safety of inositol for cats. 
Supplementing  feed  for  fish  and  crustaceans  will  not  substantially  increase  the  exposure  of  the 
consumer  to  inositol.  Considering  dietary  exposure  and  endogenous  synthesis  of  inositol,  the 
additional exposure from fish fed inositol-supplemented diets is of no concern for consumer safety. 
Considering the potential inhalation exposure upon handling the additive and the absence of data on 
inhalation  toxicity,  the  FEEDAP  Panel  concludes  that  inhalation  exposure  from  handling  inositol 
could be hazardous. In the absence of data, inositol should be considered as irritant to skin and eyes 
and as a skin sensitiser. 
                                                       
28 Regulation  (EC)  No 183/2005  of  the  European  Parliament  and  of  the  Council  of  12  January  2005  laying  down 
requirements for feed hygiene. OJ L 35, 8.2.2005, p. 1. Inositol for fish, dogs and cats 
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Inositol occurs naturally in the environment, particularly in plants. The use of inositol in fish nutrition 
is  not  expected  to  substantially  increase  the  concentration  in  the  environment.  Consequently,  the 
supplementation of fish feed with inositol does not pose a risk to the environment. 
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APPENDIX 
Executive Summary of the Evaluation Report of the European Union Reference Laboratory for 
Feed Additives on the Method(s) of Analysis for inositol
29 
In the current application authorisation is sought under articles 4(1) and 10(2) for Inositol under the 
category/functional  group  3(a)  ‘nutritional  additives’/‘vitamins,  pro-vitamins  and  chemically  well 
defined substances having similar effect’ according to Annex I of Regulation (EC) No 1831/2003. 
Authorisation  is  sought  for  the  use  of  the  feed  additive  for  all  animal  species  and  categories. 
According to the Applicant, Inositol is an odourless white crystalline powder with a minimum purity 
of  97  %.  The  feed  additive  is  intended  to  be  incorporated  in  premixtures  and  feedingstuffs.  The 
Applicant  did  not  specify  any  minimum  or  maximum  concentrations  of  Inositol  in  feedingstuffs, 
however,  the  following  doses  were  recommended:  from  350–500  mg  /kg  for  salmonids  and  a 
maximum of 1000 mg/kg for laying hens. 
For the quantification of Inositol in the feed additive, premixtures and feedingstuffs the Applicant 
proposed  a  single-laboratory  validated  and  further  verified  method  based  on  the  microbiological 
activity  analysis.  The  following  performance  characteristics  were  reported  for  feed  additive, 
premixtures and feedingstuffs: 
  a relative standard deviation for repeatability (RSDr) ranging from 1.9 to 9.5 %; 
  a relative standard deviation for intermediate precision (RSDip) ranging from 1.2 to 16.2 %; 
  a recovery rate (Rrec) ranging from 82 to 119 %; and  
  a limit of detection and quantification (LOD and LOQ) of 4 and 8 mg/kg, respectively. 
Additionally,  for the identification  of  Inositol,  the  EURL  identified  the internationally  recognised 
European  Pharmacopoeia  method  (Ph.  Eur.  01/2008:1805),  based  on  liquid  chromatography  and 
infrared absorption spectrophotometry. Even though no performance characteristics are provided the 
EURL considers this method to be suitable within the frame of official control. 
Based on these performance characteristics, the EURL recommends for official control the European 
Pharmacopeia method (monograph 1805) based on liquid chromatography for the identification of 
Inositol in feed additive and the single-laboratory validated and further verified method based on 
microbiological activity analysis for the quantification of Inositol in feed additive, premixtures and 
feedingstuffs.  
Further  testing  or  validation  of  the  methods to  be performed  through  the consortium  of  National 
Reference Laboratories as specified by article 10 (Commission Regulation (EC) No 378/2005) is not 
considered necessary. 
                                                       
29 The  full  report  is available on  the  EURL  website:  http://irmm.jrc.ec.europa.eu/SiteCollectionDocuments/FinRep-FAD-
2010-0196.pdf 